{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T06:11:24Z","timestamp":1778134284282,"version":"3.51.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T00:00:00Z","timestamp":1769299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Eribulin is an approved treatment option for soft tissue sarcomas (STSs) in Japan; however, real-world data regarding its safety, efficacy, and optimal dosing strategies across heterogeneous patient populations remain limited. Thus, this study aimed to evaluate clinical outcomes, treatment tolerability, and prognostic factors in patients with STS treated with eribulin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed 50 patients with STS who received eribulin at a single institution between 2018 and 2024. Clinical variables, dosing schedules, tumor responses, survival outcomes, and adverse events (AEs) were analyzed. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan\u2013Meier method; group comparisons were performed with the log-rank test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort had a median age of 66 years, and eribulin was administered as first-line therapy in 24 patients. The disease control rate was 62%; one patient achieved complete response and one achieved partial response. Median PFS and OS were 4 and 19 months, respectively. Hematologic toxicities were the most common Grade \u2265\u00a03 AEs, with no treatment-related cardiac events observed. Dose modifications included a bi-weekly schedule or a regimen consisting of two administrations followed by a 2-week rest period with pegfilgrastim support. No treatment discontinuations due to AEs occurred in either reduced-intensity schedule; the latter regimen demonstrated the longest treatment duration. Survival outcomes were comparable across age groups, treatment lines, histological subtypes, and tumor locations. Patients aged \u226570 years achieved a median OS of 16 months, generally consistent with previously reported outcomes in elderly sarcoma populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Eribulin demonstrated favorable tolerability and durable disease control across diverse patient subgroups, including elderly and comorbid patients who are often ineligible for anthracycline therapy. Although no significant prognostic factors were identified, bi-weekly dosing and two-administration\/2-week rest schedules were feasible, with the latter offering the advantage of pegfilgrastim support. These findings support the integration of eribulin into individualized treatment strategies for advanced STS and highlight the need for prospective studies to refine patient selection and optimize dosing approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyag001","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:27:58Z","timestamp":1767702478000},"page":"569-576","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcome of 50 patients treated with eribulin for soft tissue sarcoma: a single-institute retrospective study"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0802-8553","authenticated-orcid":false,"given":"Yudai","family":"Murayama","sequence":"first","affiliation":[{"name":"Division of Musculoskeletal Oncology and Orthopedic Surgery , Tochigi Cancer Center, 4-9-13 Yonan, Utsunomiya, Tochigi 320-0834,","place":["Japan"]},{"name":"Division of Orthopedic Surgery , Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata 951-8510,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rumi","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal Oncology and Orthopedic Surgery , Tochigi Cancer Center, 4-9-13 Yonan, Utsunomiya, Tochigi 320-0834,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutaka","family":"Sukawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology , National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo 152-8902,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology , Yamagata University Hospital, 2-2-2 Iida-nishi, Yamagata 990-9585,","place":["Japan"]},{"name":"Department of Medical Oncology , Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8574,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Division of Orthopedic Surgery , Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata 951-8510,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Kikuta","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal Oncology and Orthopedic Surgery , Tochigi Cancer Center, 4-9-13 Yonan, Utsunomiya, Tochigi 320-0834,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,25]]},"reference":[{"key":"2026050701221771600_ref1","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1002\/cncr.30191","article-title":"Chemotherapy for soft tissue sarcoma","volume":"122","author":"Ratan","year":"2016","journal-title":"Cancer"},{"key":"2026050701221771600_ref2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11936-014-0315-4","article-title":"Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment","volume":"16","author":"Raj","year":"2014","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"2026050701221771600_ref3","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2013.55.0459","article-title":"Cardiac effects of anticancer therapy in the elderly","volume":"32","author":"Accordino","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026050701221771600_ref4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3322\/caac.21605","article-title":"Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine","volume":"70","author":"Gamboa","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"2026050701221771600_ref5","doi-asserted-by":"publisher","first-page":"869754","DOI":"10.3389\/fphar.2022.869754","article-title":"Efficacy of eribulin in soft tissue sarcomas","volume":"13","author":"Phillips","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026050701221771600_ref6","doi-asserted-by":"publisher","first-page":"20896","DOI":"10.1038\/s41598-020-77898-y","article-title":"Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin","volume":"10","author":"Tsuchihashi","year":"2020","journal-title":"Sci Rep"},{"key":"2026050701221771600_ref7","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"key":"2026050701221771600_ref8","doi-asserted-by":"publisher","first-page":"6384","DOI":"10.1158\/1078-0432.CCR-16-2422","article-title":"FDA approval summary: Eribulin for patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen","volume":"23","author":"Osgood","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026050701221771600_ref9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline. Version 1.1","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026050701221771600_ref10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"2026050701221771600_ref11","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1186\/s12885-022-09527-y","article-title":"Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study","volume":"22","author":"Kawai","year":"2022","journal-title":"BMC Cancer"},{"key":"2026050701221771600_ref12","doi-asserted-by":"publisher","first-page":"11551","DOI":"10.1200\/JCO.2024.42.16_suppl.11551","article-title":"Results of a randomized phase II trial of 2nd-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib: Japan clinical oncology group study JCOG1802 (2nd-STEP)","volume":"42","author":"Endo","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026050701221771600_ref13","doi-asserted-by":"publisher","first-page":"e7295","DOI":"10.1002\/cam4.7295","article-title":"Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline\/taxanes","volume":"13","author":"Chen","year":"2024","journal-title":"Cancer Med"},{"key":"2026050701221771600_ref14","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s12282-018-0843-y","article-title":"Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY)","volume":"25","author":"Ohtani","year":"2018","journal-title":"Breast Cancer"},{"key":"2026050701221771600_ref15","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10585-019-09980-3","article-title":"The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai musculoskeletal oncology consortium study","volume":"36","author":"Nakamura","year":"2019","journal-title":"Clin Exp Metastasis"},{"key":"2026050701221771600_ref16","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1634\/theoncologist.2017-0598","article-title":"Outcomes of elderly patients with advanced soft tissue sarcoma treated with first-line chemotherapy: a pooled analysis of 12 EORTC soft tissue and bone sarcoma group trials","volume":"23","author":"Younger","year":"2018","journal-title":"Oncologist"},{"key":"2026050701221771600_ref17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s12282-022-01357-x","article-title":"Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study","volume":"29","author":"Kikawa","year":"2022","journal-title":"Breast Cancer"},{"key":"2026050701221771600_ref18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.52586\/S559","article-title":"Multifarious targets beyond microtubules-role of eribulin in cancer therapy","volume":"13","author":"Seshadri","year":"2021","journal-title":"Front Biosci (Schol Ed)"},{"key":"2026050701221771600_ref19","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1200\/JCO.2016.71.6605","article-title":"Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine","volume":"35","author":"Demetri","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026050701221771600_ref20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3892\/mco.2020.2175","article-title":"Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line. Mol","volume":"14","author":"Nakano","year":"2021","journal-title":"Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/5\/569\/66569312\/hyag001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/5\/569\/66569312\/hyag001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T05:22:23Z","timestamp":1778131343000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/5\/569\/8440736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,25]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,1,25]]},"published-print":{"date-parts":[[2026,5,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag001","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,1,25]]}}}